Additionally, it demonstrated equivalent antitumor efficacy to that of the commercially available anti-CTLA-4 MAB (Ipilimumab Yervoy®) in a humanized murine tumor model, implying that the plant-derived anti-CTLA-4 MAB has similar therapeutic potential to that of the clinically efficient Ipilimumab. This evidence concerns the gene CTLA4 and neoplasm.